

## Ataxin 1 (ATXN1) Antibody

Catalogue No.:abx031721





The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known.

Target:	Ataxin 1 (ATXN1)
Clonality:	Polyclonal
Reactivity:	Human
Tested Applications:	ELISA, WB, IF/ICC
Host:	Rabbit
Recommended dilutions:	WB: 1/2000, IF/ICC: 1/10 - 1/50. Optimal dilutions/concentrations should be determined by the end user.
Conjugation:	Unconjugated
Immunogen:	KLH-conjugated synthetic peptide between 754-781 amino acids from human ATXN1.

## Datasheet Version: 3.0.0 Revision date: 26 Jun 2025



Isotype:	lgG
Form:	Liquid
Purification:	Purified through a protein A column, followed by peptide affinity purification.
Storage:	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
UniProt Primary AC:	P54253 ( <u>UniProt</u> , <u>ExPASy</u> )
KEGG:	hsa:6310
String:	9606.ENSP00000244769
Molecular Weight:	Calculated MW: 86.9 kDa
Buffer:	PBS containing 0.09% sodium azide.
Note:	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.